PHPeng Han

Peng Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peng Han has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Baixin Shen

    Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China

    1 shared publication
  • Chao Qin

    Nanjing Medical University

    1 shared publication
  • Chengcheng Yang

    Department of Urology, Jiangsu Key Laboratory of Urological Disease Prevention and Treatment, The Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, 210008 Nanjing, Jiangsu, China

    1 shared publication
  • Chengdi Yang

    Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China

    1 shared publication
  • Jie Xu

    Department of Urology, Jiangsu Key Laboratory of Urological Disease Prevention and Treatment, The Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, 210008 Nanjing, Jiangsu, China

    1 shared publication
  • Jiexiu Zhang

    Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China

    1 shared publication

Latest Publications

  • Open Access

    Iguratimod Modulates M1 Macrophage Polarization Via the NOTCH4–KLF4 Axis to Alleviate Antibody-Mediated Rejection

    by Zhou Hang, Junqi Zhang, Chengcheng Yang, Ming Zheng, Zexin Yang, Jie Xu, Peng Han, Min Gu

    Background: Iguratimod (IGT) is a small-molecule anti-inflammatory agent that effectively attenuates the progression of antibody-mediated rejection (ABMR). However, the underlying mechanism of action of IGT remains poorly understood. Thus, this study aimed to investigate the mechanism through which IGT regulates macrophage polarization and ABMR. Methods: A mouse model of ABMR was established by performing kidney transplantation after skin graft-induced sensitization. Experimental interventions included neurogenic locus notch homolog protein 4 (NOTCH4) knockout mice and oral administration of IGT. RNA sequencing, quantitative polymerase chain reaction, Western blotting (WB), flow cytometry, and immunofluorescence (IF) staining were performed to investigate M1 macrophage polarization and the Jagged1–NOTCH4 signaling pathway. Results: This study found that IGT significantly reduced M1 macrophage infiltration into renal allografts in a mouse model of ABMR. Transcriptomic sequencing and subsequent biological experiments indicated that IGT may regulate macrophage polarization through the Jagged1–NOTCH4 pathway. Conclusion: M1 macrophage polarization may contribute to the initiation and progression of ABMR following kidney transplantation. IGT attenuates M1 macrophage polarization by inhibiting Jagged1–NOTCH4–Krüppel-like Factor 4 (KLF4) signaling.

  • Open Access

    RTA‐408 Protects Kidney from Ischemia‐Reperfusion Injury in Mice via Activating Nrf2 and Downstream GSH Biosynthesis Gene

    by Peng Han, Zhiqiang Qin, Jingyuan Tang, Zhen Xu, Ran Li, Xuping Jiang, Chengdi Yang, Qianwei Xing, Xiaokang Qi, Min Tang, et al.

    Acute kidney injury (AKI) induced by ischemia‐reperfusion is a critical conundrum in many clinical settings. Here, this study aimed to determine whether and how RTA‐408, a novel oleanane triterpenoid, could confer protection against renal ischemia‐reperfusion injury (IRI) in male mice. Mice treated with RTA‐408 undergoing unilateral ischemia followed by contralateral nephrectomy had improved renal function and histological outcome, as well as decreased apoptosis, ROS production, and oxidative injury marker compared with vehicle‐treated mice. Also, we had found that RTA‐408 could strengthen the total antioxidant capacity by increasing Nrf2 nuclear translocation and subsequently increased Nrf2 downstream GSH‐related antioxidant gene expression and activity. In vitro study demonstrated that GSH biosynthesis enzyme GCLc could be an important target of RTA‐408. Furthermore, Nrf2‐deficient mice treated with RTA‐408 had no significant improvement in renal function, histology, ROS production, and GSH‐related gene expression. Thus, by upregulating Nrf2 and its downstream antioxidant genes, RTA‐408 presents a novel and potential approach to renal IRI prevention and therapy.